Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions
November 17, 2019 15:05 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 17, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American...
Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results
November 12, 2019 11:05 ET
|
Esperion Therapeutics, Inc.
– Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP – – Over 52-Weeks, Overall Adverse Events in the Bempedoic Acid Treatment Arm were Comparable to...
Esperion to Participate in Upcoming Investor Conferences
November 07, 2019 07:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), today announced that the company will participate in fireside chats at the following conferences: Credit Suisse 28th...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results
November 06, 2019 07:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the third quarter ended...
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions
November 04, 2019 07:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American...
Esperion to Report Third Quarter 2019 Financial Results November 6, 2019
October 29, 2019 07:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets...
Esperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid
September 05, 2019 07:30 ET
|
Esperion Therapeutics, Inc.
– 14,032 Patients are Now Fully Enrolled in the CLEAR Cardiovascular Outcomes Trial –– Expect CLEAR Cardiovascular Outcomes Trial to Conclude in the Second Half of 2022 – ANN ARBOR, Mich., Sept. 05,...
Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes
August 29, 2019 07:30 ET
|
Esperion Therapeutics, Inc.
— Bempedoic Acid / Ezetimibe Combination Tablet Achieved Robust 40% Placebo Corrected LDL-C Lowering —— Provided 25% hsCRP Reduction —— No Worsening of Glycemic Control —— Overall Adverse Events...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results
August 08, 2019 07:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the second quarter ended June...
Esperion to Present at the BTIG Biotechnology Conference
August 06, 2019 16:15 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will participate in a lipid panel discussion with investors at the BTIG Biotechnology...